Business context and reporting period
Tenaya Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter and six months ended June 30, 2021. The preclinical-stage biotechnology company is developing heart-disease therapies across gene therapy, cellular regeneration and precision medicine. It had no approved products and generated no revenue.
Financial results and liquidity
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $10.9m | $7.0m | $20.5m | $14.3m |
| General and administrative expense | $4.3m | $1.9m | $7.8m | $3.9m |
| Total operating expenses | $15.2m | $8.9m | $28.3m | $18.1m |
| Net loss | $15.2m | $8.7m | $28.3m | $17.8m |
| Basic and diluted loss per share | $13.26 | $9.21 | $25.21 | $19.32 |
Margins are not meaningful because the company had no revenue. For the six months, operating cash use was $27.8m; investing cash use was $7.6m, primarily for property and equipment; financing provided $18.7m, including $20.0m net proceeds from Series C preferred stock, partly offset by deferred IPO costs. Cash, cash equivalents and restricted cash ended the period at $112.4m, including $111.9m of cash and cash equivalents.
At June 30, 2021, total assets were $156.9m, current assets $113.2m, current liabilities $9.8m and total liabilities $24.7m. The company reported no debt borrowings; operating lease liabilities totaled $16.5m. Accumulated deficit was $111.1m.
Material changes versus prior comparable periods
- Q2 net loss increased $6.5m, or 74%, year over year; six-month net loss increased $10.5m, or 59%.
- Q2 R&D expense rose 57%, primarily from higher facility and laboratory costs, personnel costs and external research costs. Six-month R&D expense rose 44%.
- Q2 G&A expense rose 126%; six-month G&A expense rose 102%, reflecting increased professional services, staffing and facilities, including costs associated with preparing to become a public company.
- Property and equipment, net, increased to $24.9m from $17.2m at year-end 2020, alongside manufacturing and office build-out. The company adopted lease accounting guidance in January 2021.
Outlook, risks and unusual items
- Management expected losses and spending to increase as programs advance, manufacturing capabilities are built and public-company costs rise. It believed June cash plus IPO proceeds would fund operations for at least 12 months from the filing date; this estimate depends on assumptions and spending could exceed expectations.
- After quarter-end, the August 3, 2021 IPO issued 13.8m shares at $15.00 per share and raised approximately $188.8m net. Preferred shares converted into 26.1m common shares. These transactions are subsequent events and are not reflected in June 30 balances.
- The company planned to submit an IND or CTA for TN-201, its lead gene-therapy candidate for genetic hypertrophic cardiomyopathy, in 2022, and planned a 2022 IND for TYA-11631, an HDAC6 inhibitor. All programs remained preclinical; timelines and outcomes were uncertain.
- Management reported modest COVID-19-related research delays, mainly from supplier lead times and temporary academic-institution shutdowns; it cautioned that further disruption could affect research, manufacturing and financing.
- Key risks include early-stage development and no clinical trials initiated, uncertain safety and efficacy, regulatory and manufacturing challenges, dependence on third parties, intellectual-property disputes, competition and the need for substantial future funding. TN-201 has orphan-drug designation, but this does not assure approval or exclusivity.
- The filing reported effective disclosure controls and no material change in internal control over financial reporting during the quarter. No material litigation was reported.
Important facts for investors to verify
- Confirm the reported cash runway assumptions and how the IPO proceeds are being deployed against the company’s expanding R&D and manufacturing plans.
- Track execution and regulatory progress toward the planned 2022 filings for TN-201 and TYA-11631, including any changes to development timelines.
- Monitor construction, qualification and operational readiness of the planned cGMP manufacturing facility, as well as reliance on external suppliers and manufacturers.
- Review future filings for cash burn, operating-lease commitments, financing needs and any new debt or collaboration terms.
- Assess dilution and ownership changes following the IPO, preferred-stock conversion, equity-plan authorizations and eventual release of share lockups.